Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't have a clue but I know Raj is still looking for great opportunities. Why else would they have raised the Authorized Shares?
IMO the company will do the share buyback but they will not retire them. The shares will be used to buy another drug. As a consequence they will not have to increase the OS that much ....
Conclusion from the article:
* As TEVA is not planning to make or sell leucovorin any time soon, SPPI should continue to benefit from the ongoing shortage. I believe SPPI’s Fusilev could end up taking significant share from TEVA’s leucovorin. Again, the numbers really say it all. To improve revenue and earnings, TEVA should acquire SPPI and obtain the rights to Fusilev. Sooner than later, I think TEVA buys SPPI.
* Right now, SPPI is a steal while trading at a mere 2.19 times Q1 2011 sales ($40 M) plus cash ($140 M). From my view, that’s crazy. Technically speaking, SPPI is likely to rebound sharply in the coming days. With a short interest near 11%, SPPI has short squeeze potential.
* With continued quarterly sales and earnings growth, SPPI will likely hit $15+.
I think you forgot to mention the possible next deal of GCD:
In the case of the second project for the building of a chain of social care ecological centers GCD hopes to sign the contract by 1 June. The total value of the contracts is 220 million euro and GCD anticipates a profit margin of 40%.
http://www.actmedia.eu/2011/05/18/top+story/american+investments+in+romania:+570+million+euro+in+wind+energy+and+social+care/33756
They are still confident in an increase of sales for Zevalin for this year.
But seems that I was wrong about that statement of 3M $
( I have to turn up music volume lol)
From CC: Sales Zevalin April 2011 3M $ and on the rise
this in comparison with 6M $ for the full 1Q2011
interesting article:
http://fightcolorectalcancer.org/uncategorized/2011/05/fda_approves_fusilev_for_colorectal_cancer
FDA Approves Fusilev for Colorectal Cancer
Posted by Kate Murphy on May 2nd, 2011
Advanced colorectal cancer is now an FDA approved indication for Fusilev® (levoleucovorin) in combination with 5-FU.
According to a news release from its manufacturer, Spectrum Pharmaceuticals, the FDA agreed to include metastatic colorectal cancer on the Fusilev label on April 29, 2011.
Although Fusilev has been used off-label during the leucovorin shortage, it is now fully FDA-approved for the palliative treatment of advanced colorectal cancer that has spread beyond the colon or rectum.
So what’s the difference?
Leucovorin is a racemate compound. Its molecule has two chemical compounds that are exact mirror images of each other, one active and one inactive. Fusilev (levoleucovorin) contains only the active part of the racemic leucovorin molecule.
It is critical that physicians and pharmacists realize that dosing for leucovorin and Fusilev are not the same. Only one half the dose of leucovorin should be given when Fusilev is used to replace racemic leucovorin.
Is Fusilev more effective?
A number of studies have found no difference between leucovorin and levoleucovorin in combination with 5-FU or alone for cancers in the gastrointestinal tract. Two randomized clinical trials direct compared the two: uncovering no differences in effect on tumor shrinkage, time until cancer got worse, survival time, or the percentage of patients who were alive one and two years after beginning treatment.
In 2009 researchers at Georgetown reviewed all the published studies of the use of levoleucovorin in gastrointestinal malignancies to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. They concluded,
In many studies of patients with gastrointestinal malignancies, levoleucovorin has been used interchangeably and solely for racemic leucovorin for 5-FU modulation. Our literature review demonstrates that levoleucovorin has similar efficacy and tolerability when compared with racemic leucovorin, whether used in combination with other chemotherapeutic agents or alone.
What about costs?
Fusilev is many times the cost of generic leucovorin, and Medicare and some insurances have been paying only a part of that cost up until now. Medicare reimburses oncology practices $750 for a dose of Fusilev, with the full cost of up to $1,200 being absorbed by some practices during the leucovorin shortage.
With FDA approval for the metastatic colorectal cancer indication, Medicare can now reimburse the full cost.
What’s the impact of the FDA decision for doctors and patients
Since 2008 there have been continuing shortages of leucovorin, which enhances the effectiveness of of 5-FU (fluorouracil). As of April this year, there were still serious problems obtaining leucovorin to treat people with colorectal cancer.
On April 19, 2011 the American Society of Health-System Pharmacists reported that leucovorin shortages continue without any expected dates when they will end. At the same time there is increased pressure on Fusilev, and Spectrum is also reporting shortages of it. The FDA has inspected an Italian Pfizer manufacturing facility and has approved temporary Fusilev imports from that facility only.
Doctors may choose to avoid risking leucovorin shortages and turn to Fusilev for their patients with advanced colorectal cancer if reimbursement is not a problem.
Hopefully, patient anxiety will be reduced, and standard treatment for colorectal cancer will be available in the United States.
What about costs?
Fusilev is many times the cost of generic leucovorin, and Medicare and some insurances have been paying only a part of that cost up until now. Medicare reimburses oncology practices $750 for a dose of Fusilev, with the full cost of up to $1,200 being absorbed by the practice during the leucovorin shortage.
With FDA approval for the metastatic colorectal cancer indication, Medicare can now reimburse the full cost. Private insurance coverage should also be available.
SOURCES: Kovoor et al., Clinical Colorectal Cancer, Volume 8, Number 4, October 2009.
PHAR news:PharmStar Pharmaceuticals CEO to Appear on the Bill Chippas Show
http://www.marketwire.com/press-release/PharmStar-Pharmaceuticals-CEO-to-Appear-on-the-Bill-Chippas-Show-1425825.htm
PharmStar Pharmaceuticals CEO to Appear on the Bill Chippas Show
Listen Live on Tuesday, April 12th at 10:20 am EDT
ROCKY MOUNT, NC--(Marketwire - April 11, 2011) - PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, announced today that its Chief Executive Officer, Howard Phykitt, will be interviewed on the Bill Chippas Show on Tuesday, April 12, 2011, which airs between 10:00 am to 11:00 am Eastern Time. Those interested in PharmStar Pharmaceuticals are encouraged to listen live tomorrow at 10:20 am ET by visiting www.billchippasshow.com or www.Princetonresearch.com.
Mr. Phykitt is the inventor Aquaprin, the signature pain reliever that is being commercialized for distribution by PharmStar. He will give insight into the development of Aquaprin and take questions from callers during his segment on the show. Callers can talk with Mr. Phykitt by calling 1-772-220-9788 or email questions during the show to Bill@Billchippasshow.com.
Since 2005, Bill has hosted the Bill Chippas Show in South Florida on AM 1590 and AM 1450. Individual investors, active traders and institutional professionals rely on Bill's timely unbiased analysis, deep rooted market background and experience spanning four decades to make intelligent and common sense investments. Bill's weekly Stock Market Comments appear in Weekly Market Strategies delivered by Princeton Research (www.princetonresearch.com) to global investors, and Bill's opinion columns appear in YourNews.com. In 1996, Bill founded FuturesCom, which remains one of today's longest running Internet-based, independent publications for investment market research. To learn more about Bill, visit www.billchippasshow.com.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
I don't deny your newsletter, the report i refer to on hotstocked:
http://www.hotstocked.com/companies/b/biomoda-inc-BMOD-51797.html
I've downloaded the newsletter on hotstocked.com and it is just based on technical analysis and is dated 29 nov 2010 !!
==> completely outdated ...
Webpage was never down for me
annotated chart of APNI plz tia
thanks for that info!
Me too sold yesterday but wanted to jump back in if today was strong. Gonna look for another one now lol
thnx. following the board since a couple of weeks now eom.
SFNN annotated chart plz... thnx
ok thanks breakout_trader & jupiler
Is there news or rumour on EHDN?
wow, unreal!!
On watch: GCOG
Is that a Magic Box forming? (yesterday and today A1_A2)
I read OS 523,000 while volume > 800000.
Weird
Hopefully the news comes not too fast...
Things are great now.. lets keep it that way for another day or two. Rome is not built in one day and i'm afraid the first pr won't do it.
Maybe its because i held thru the painful times of last 2 months that i'm a little sceptical but i must admit: this steady rise is not just made upon air IMO.
Include me please. thx eom
It seems that I need to change my timeline.
We didn't have full confirmation yet about the share reductions
--> still 34 mil. to go (from 395 mil. to 361 mil.)
Hoping and looking for this:
The sooner, the better..
Good luck to all!
yep eom
They just removed them because we haven't got official confirmation by the company.
Today, GBDX jumped just above 20ema. Increasing volume over the past 4 days, 'big' buys at end of day, most indicators looking good, bollinger bands tight but something is keeping the rsi under 50 since 21dec06. Dilution, (naked)shorting, etc who knows...but there still remains a pr claiming a reduction of shares (although having difficulties to execute it for the moment as a I read on the board)
It will be very interesting tomorrow to see what will happen. Hopefully not the same as last friday jumped back to where it was.
Not a buy or sell recommendation
MGM Mineral Resources Announces Early 2007 Corporate Update
2007-01-16 13:09 ET - News Release
TORONTO -- (MARKET WIRE) -- 01/16/07
Metro Gold Mines Mineral Resources Inc. (PINKSHEETS: MGMX) is a growing gold mining company engaged in the acquisition and development of production properties in South and Central America.
The Company is pleased to announce that the CEO, President, Director of Operations, and other key management participated in a conference call yesterday to determine the outlook and objectives for 2007. All issues were discussed pertaining to exploration, production, price per share, shareholder confidence, safety and environmental policies, as well as the reorganization of various departments.
The start-up of operations throughout 2006 at the various mining sites has continued in the ordinary course. There were many substantive milestones that were achieved by MGM Mineral Resources, including the acquisition of seven properties, all with different exploration and extraction opportunities. The Company's initial property, La Esperanza, still remains as the site that could catapult MGM into becoming a high-yielding operation.
"For this to occur, it was decided in the conference call by our Directors that the Company will continue its process of reassessing the La Esperanza Mine and its reserves," says Mr. Ken Lamb, President of MGM Mineral Resources. "The purpose of reassessing the land and reserves would be to better formulate a proper drilling and mining program. Metro Gold Mines has been actively seeking a third party geologist to visit La Esperanza, as well as the other properties, which could then raise shareholder confidence and confirm to the world that the Company will be a force in the coming years."
A new reserve estimate and mine plan for the La Esperanza mine is planned for second quarter of 2007. The Company anticipates a mine plan that will include a drilling program, raise production levels and renew reserve estimates.
Las Malvinas was already in production when Metro Gold Mines acquired the mining rights and early estimates show that 2007 will be a very productive year for this property. The Company will release figures to its shareholders regarding mining rates for this property.
Many adjustments have been made to the various systems such as the water pumps, conveyors and pipelines for delivery of ore and water for ore processing at the plant. All adjustments and refinements continue to be made in the ordinary course for the proper operation of the plant. Las Malvinas remains on track to become a high-yielding operation by third quarter of 2007.
Exploration, small scale production and cost improvements continue throughout the various MGM properties, including improved processes to increase safety and reduce risk of damage to equipment.
"Our operation is now focusing primarily on completing gold recovery in Las Malvinas and renewing reserve estimates at La Esperanza and on our other properties," continues Mr. Ken Lamb. "There is also ongoing behind-the-scenes work with government authorities regarding environmental and other licensing issues, especially when negotiating with upcoming lands. MGM is now in a much better position than it was in throughout 2006 after implementing a number of initiatives. Such initiatives will have a positive impact on the balance sheet and income statement throughout 2007 and in turn should reflect in the Company's price per share which is of great interest to our shareholders who have been very patient." The Company is also considering setting up by Q2 07, an advisory board comprised of geologists, drill experts and ex-government officials that would oversee an efficient and productive work program on the Company' properties.
Throughout the conference call, management expressed great concern with the current price per share and understands that geological and financial data need to be quantified by independent third parties before being released. MGM is aware that releasing precise geological data, production numbers and updated financial information will play a major role in the share price. Geological data, production and financial information will be released to the public in short time once the 2006 information has been completed and filed.
About MGM Mineral Resources (PINKSHEETS: MGMX)
Metro Gold Mines Mineral Resources Inc. is a growing, expertly managed gold mining company focused on acquiring and producing an impressive portfolio of exploration and production properties in South and Central America. MGM Mineral Resources is working to establish itself as a world-class gold company, capitalizing on smart acquisitions, breakthrough technology, modernized operations, deep industry expertise and a strong gold market to cost-effectively produce high quality gold. The company has identified a significant opportunity to exploit proven but under-developed mineral resources in Colombia. MGM Mineral Resources was initially targeting the richest gold zone in Colombia, Segovia, but, is now extending to other areas throughout the country. For more information please visit www.mgmmining.com
Forward-Looking Statements
Statements contained in this news release, which are not historical facts, are forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 that involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things: volatility and sensitivity to market prices for gold; replacement of reserves; procurement of required capital equipment and operating parts and supplies; equipment failure; unexpected geological or hydrological conditions; political risks arising from operating in certain developing countries; imprecision in reserve estimates; success of future exploration and development initiatives; competition; operating performance of the facilities; environmental and safety risks including increased regulatory burdens; seismic activity, weather and other natural phenomena; failure to obtain necessary permits and approvals from government authorities; changes in government regulations and policies including tax and trade laws and policies; ability to maintain and further improve positive labor relations; and other development and operating risks. Although MGM Mineral Resources believes that the assumptions inherent in the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this report. The company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Mr. Kenneth Lamb
President
416-214-7847
About the supply the first half of 2007 (De Beers 11dec2006)
De Beers says diamond supply to tighten in H1 2007
JOHANNESBURG, Dec 11 (Reuters) - The world's biggest diamond producer De Beers has told clients it expects a reduced supply of rough diamonds to distribute during the first half of next year as it curtails marketing of Russian gems under an EU deal.
The Diamond Trading Company (DTC), the De Beers marketing arm, has set out intended amounts of diamonds it will offer to its so-called sightholders, or specially selected clients, De Beers told Reuters.
"In some instances the level... has been lower than anticipated by DTC sightholders, because the DTC anticipates a lower availability of rough diamonds to sell in H1 2007," De Beers said. De Beers said part of the reason for the reduced supply was a deal agreed last year with the European Commission to phase out marketing of rough diamonds from Russia's Alrosa to settle a long-running monopoly abuse case.
Under the agreement, De Beers' purchases of Alrosa rough diamonds will fall from $600 million in 2006 to $500 million in 2007, $400 million in 2008 and to zero in 2009.
Reuters Pictures
Photo
Editors Choice: Best pictures
from the last 24 hours.
View Slideshow
In addition, lower production is forecast from Botswana, which accounts for the bulk of De Beers mining output.
Canadian production will not yet be available in the first half of 2007, De Beers added.
The group said last month that it expected its new Snap Lake Arctic mine to start producing in October 2007 with output of 1.5 million carats when it hit full production.
Another issue reducing supply to international clients is that De Beers has pledged to southern African diamond producing countries to provide gems directly to local cutting and polishing operations to boost employment and economic growth.
De Beers is 45 percent owned by the world's third biggest mining group Anglo American Plc (AAL.L: Quote, Profile , Research), 40 percent by South Africa's Oppenheimer family and 15 percent by the government of Botswana.
http://today.reuters.com/news/articleinvesting.aspx?type=companyNews&storyid=131106+11-Dec-2006+...
Russia scraps quotas on precious metals exports
(Reuters)
13 January 2007
MOSCOW - Russia has scrapped export quotas on precious metals and diamonds, the Kremlin’s press service said on Saturday.
President Vladimir Putin has signed a decree allowing unlimited exports of most uncut diamonds, platinum group metals and other precious metals and ores.
Exports will still require a licence from the Ministry of Economic Development and Trade, the Kremlin said in a statement.
Previously, the Russian government set long-term quotas for exports of precious metals and uncut diamonds.
These were already large enough to accommodate exports from Russia’s biggest palladium and platinum miner, Norilsk Nickel GMKN.RTS, and state diamond trader Almazyuvelirexport so analysts have said their removal is unlikely to have a major impact.
The statement said the decree would become effective from the day of signing. It did not say exactly when Putin signed the document.
http://www.khaleejtimes.com/DisplayArticleNew.asp?xfile=data/business/2007/January/business_January2...
It was me that added you to my list. I didn't do it already because i frequently read the board and enjoy your good info.
Keep up the good work!
Good thinking! And if that is indeed possible, a negative outcome of the lawsuit wouldn't harm us at all (except maybe the upfront payment but not the royalty).
Large volume? I didn't even think that we would uptick to .0004 on a 100M shares.
Accumulation is the key nowadays. If you accumulate more at this price ranges (.0003 - .0006) you'll be much more comfortable to sell a few shares when we go higher IMO
If one big player jumps in, others follow..
+ a lot of traders who are practically certain they'll make a decent profit within the year 2007. This is only the beginning IMHO. We just needed some trigger that will cause this effect, again in my opinion.
Good luck!
Ouch.. Half a year ago we had NOBO's, then RM's, what's next? LOL